Lonza to expand bioconjugation capabilities at Visp site

CDMO will add two production suites for clinical and commercial supply and extend lab space to double analytical and process development capacity
CDMO Lonza is expanding bioconjugation capabilities at its development and manufacturing site in Visp, Switzerland by adding two production suites providing development and manufacturing infrastructure for clinical and commercial supply as well as extending laboratory space to double the analytical and process development capacity.
The new capacity is expected to be fully operational from the first half of 2022.
The manufacturing extension spans approximately 1500m2 and adds 30% additional capacity while an additional support building of 5000m2 will provide space for logistics, storage and other supporting infrastructure.
Lonza said the “highly flexible” setup will enable bioconjugation processes using single-use, stainless steel and hybrid concepts.
In a statement, Stefan Egli, Head Business Unit Bioconjugates, Lonza, said bioconjugation is used to develop a growing pipeline of complex protein therapeutics such as antibody-drug conjugates (ADCs).
ADcs are a class of biopharmaceutical drugs specifically designed to target and kill tumour cells while sparing healthy ones.
The CDMO said the expansion complements its recent expansion of customer-specific suites as part of the Ibex Dedicate model.
“In addition, expansions in payload manufacturing capacity and drug product sterile fill and finish will support the increasing development and manufacturing needs for bioconjugates,” the company said.
“Lonza started to offer CDMO services for ADCs back in 2006 and we now manufacture the majority of the currently commercially approved ADCs,” said Iwan Bertholjotti, Director Commercial Development Bioconjugates at Lonza. “The field goes beyond ADC’s and Lonza has the expertise to support customers bringing a range of different bioconjugates to market.”
The CDMO said it has produced over 600 cGMP batches of bioconjugated products for over 60 different projects since 2006.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance